Healthcare / Medical DistributionBSE
$36.04
+1.71 (+4.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $44.8M · quality 35.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$721M
P/E
8.9x
↓EV/EBITDA
4.7x
↓ROE
15.5%
↑Gross Margin
71.6%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.7%
FCF CAGR
+18.6%
FCF margin
11.9%
FCF / Net income
0.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $405.8M · net income $107.3M · FCF $48.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $405.8M | $405.8M | $439.5M | $301.7M | $276.1M |
| Net Income | $107.3M | $107.3M | $125.0M | $31.1M | $25.7M |
| EBITDA | $117.8M | $117.8M | $167.1M | $43.9M | $41.6M |
| EPS | 6.63 | 6.63 | 6.25 | 1.56 | 1.29 |
| Gross Margin | 71.6% | 71.6% | 72.6% | 69.9% | 68.2% |
| Operating Margin | 27.9% | 27.9% | 37.5% | 13.8% | 13.9% |
| Net Margin | 26.4% | 26.4% | 28.4% | 10.3% | 9.3% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.01 | 0.08 |
| Current Ratio | 7.33 | 7.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $48.5M | $48.5M | $-39.5M | $44.8M | $29.1M |
| Returns | |||||
| ROE | 15.5% | 15.5% | 72.8% | 67.7% | 173.0% |
| Valuation | |||||
| P/E | 8.92 | 8.92 | — | — | — |
| EV/EBITDA | 4.69 | 4.69 | — | — | — |
| P/B | 0.84 | 0.84 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -7.7% | -7.7% | 45.7% | 9.2% | — |
| EPS Growth | 6.1% | 6.1% | 301.4% | 21.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-21.6%
EPS terminal req.
$3.20
Spread vs growth
27.7%
5Y implied EPS CAGR
-10.2%
EPS terminal req.
$3.87
Spread vs growth
16.3%
10Y implied EPS CAGR
-0.6%
EPS terminal req.
$6.23
Spread vs growth
6.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.8%
Start / end P/E
13.3x → 5.4x
EPS bridge
6.25 → 6.63
Residual
-3.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.